AbCellera Biologics (ABCL) Accounts Payables: 2020-2024

Historic Accounts Payables for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $55.0 million.

  • AbCellera Biologics' Accounts Payables fell 1.22% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 1.22%. This contributed to the annual value of $55.0 million for FY2024, which is 10.94% up from last year.
  • AbCellera Biologics' Accounts Payables amounted to $55.0 million in FY2024, which was up 10.94% from $49.6 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Accounts Payables registered a high of $55.0 million during FY2024, and its lowest value of $20.2 million during FY2020.
  • Its 3-year average for Accounts Payables is $52.4 million, with a median of $52.5 million in 2022.
  • Per our database at Business Quant, AbCellera Biologics' Accounts Payables spiked by 63.97% in 2022 and then declined by 5.56% in 2023.
  • Over the past 5 years, AbCellera Biologics' Accounts Payables (Yearly) stood at $20.2 million in 2020, then spiked by 58.54% to $32.0 million in 2021, then skyrocketed by 63.97% to $52.5 million in 2022, then fell by 5.56% to $49.6 million in 2023, then rose by 10.94% to $55.0 million in 2024.